Participant flow

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma · Source last updated 2017-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   R-CHOP: Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients are evaluated 3 weeks after the last course of therapy. Patients with progressive disease go off study. Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8. Radiotherapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy.

   id

   FG000

   title

   Treatment

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Patient ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Insurance company refused to cover

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         62

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         53

      type

      Eligible and Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         48

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      NOT COMPLETED

   title

   Step 1 - R-CHOP

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Patient ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Other

   milestones

   1. achievements

      1. comment

         This includes all patients who received step 2 treatment regardless of eligibility.

         group Id

         FG000

         num Subjects

         56

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         48

      type

      Eligible and Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         45

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Step 2 - Zevalin™ Radioimmunotherapy

3. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Step 3 - Radiation Therapy

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice